Citadel Advisors
VTGN icon

Citadel Advisors’s VistaGen Therapeutics VTGN Stock Holding History

Citadel Advisors’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.41K Sell
15,100
-20,600
-58% -$12.4K ﹤0.01% 13547
2026
Q1 		$20.4K Sell
35,700
-429,400
-92% -$261K ﹤0.01% 12666
2025
Q4 		$308K Buy
465,100
+365,600
+367% +$1.32M ﹤0.01% 10088
2025
Q3 		$353K Buy
99,500
+63,600
+177% +$190K ﹤0.01% 9974
2025
Q2 		$71.8K Buy
35,900
+34,700
+2,892% +$78.8K ﹤0.01% 11568
2025
Q1 		$3K Sell
1,200
-53,400
-98% -$151K ﹤0.01% 13995
2024
Q4 		$161K Sell
54,600
-900
-2% -$2.53K ﹤0.01% 10779
2024
Q3 		$167K Buy
55,500
+26,700
+93% +$91.1K ﹤0.01% 10418
2024
Q2 		$100K Buy
28,800
+4,900
+21% +$21.2K ﹤0.01% 10918
2024
Q1 		$126K Sell
23,900
-14,800
-38% -$71.2K ﹤0.01% 11040
2023
Q4 		$199K Sell
38,700
-11,300
-23% -$42.8K ﹤0.01% 9966
2023
Q3 		$262K Buy
+50,000
New +$222K ﹤0.01% 9407
2022
Q4 		– Sell
-1,307
Closed -$6K – 15518
2022
Q3 		$6K Sell
1,307
-2,420
-65% -$24K ﹤0.01% 12351
2022
Q2 		$98K Buy
3,727
+2,714
+268% +$95.8K ﹤0.01% 11431
2022
Q1 		$38K Sell
1,013
-1,317
-57% -$57.4K ﹤0.01% 12971
2021
Q4 		$136K Sell
2,330
-1,457
-38% -$94.8K ﹤0.01% 12389
2021
Q3 		$311K Buy
+3,787
New +$329K ﹤0.01% 11002

Other funds holding VTGN

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
LM
Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Citadel Advisors's VTGN Position: Q2 2026 in Review

Citadel Advisors opened a new position in VistaGen Therapeutics (VTGN) in Q2 2026: 68,839 shares worth $15.6K. The stake represents ﹤0.01% of the portfolio and ranks #13453 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in VTGN as recently as Q3 2025.

Citadel Advisors first reported a position in VTGN in Q3 2017 and has held it in 19 quarters since. The position peaked at $3.93M in Q1 2024. 49 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • Citadel Advisors held 68,839 shares of VistaGen Therapeutics worth $15.6K as of Q2 2026.
  • VistaGen Therapeutics was a new Citadel Advisors position in Q2 2026.
  • VistaGen Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13453 holding.
  • Citadel Advisors first reported a position in VistaGen Therapeutics in Q3 2017 and has held it in 19 quarters since.
  • Citadel Advisors's VistaGen Therapeutics position peaked at $3.93M in Q1 2024.
  • 49 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.